Sue Dillon, Karyn O'Neil steer fledgling Aro Biotherapeutics to $13M debut — with J&J's blessing
When news first broke that R&D heavyweights Sue Dillon and Karyn O’Neil left J&J to launch Aro Biotherapeutics, precious little was known about the company except that it’s working with a new class of antibody alternatives called Centyrins. Ten months later, the Philadelphia-based biotech has finally pulled the curtain for a better look at its tech — and the team that has since come together.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
